Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Calliditas Therapeutics
LC8ACurrent price
35 EUR
-0.42 EUR (-1.13%)
Last closed
40 USD
Company
www.calliditas.se
ISIN
US13124Q1067
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
1 096 594 688 USD
Yield for 12 month
+133.10 %
1Y
3Y
5Y
10Y
15Y
LC8A
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation. Address: Kungsbron 1, D5, Stockholm, Sweden, 111 22
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
39.25 USDP/E ratio
–Dividend Yield
–Current Year
+111 320 922 USD
Last Year
+74 055 944 USD
Current Quarter
+51 632 981 USD
Last Quarter
+27 254 573 USD
Current Year
+104 213 339 USD
Last Year
+72 653 835 USD
Current Quarter
+46 703 045 USD
Last Quarter
+25 962 134 USD
Key Figures LC8A
1 year
3 years
5 years
10 years
EBITDA
-365 368 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-13.41 %
PEG Ratio
–
Return On Equity TTM
-157.2 %
Wall Street Target Price
39.25 USD
Revenue TTM
1 601 414 016 USD
Book Value
1.98 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
107.8 %
Dividend Yield
–
Gross Profit TTM
787 678 000 USD
Earnings per share
-1.76 USD
Diluted Eps TTM
-1.76 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-30 %
Dividend Analytics LC8A
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LC8A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation LC8A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
14.6413
Enterprise Value Revenue
7.0892
Price Sales TTM
0.6848
Enterprise Value EBITDA
-0.8043
Price Book MRQ
103.1085
Financials LC8A
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LC8A
For 52 weeks
16 USD
43 USD
50 Day MA
39.65 USD
Shares Short Prior Month
8 873
200 Day MA
29.6 USD
Short Ratio
0.3
Shares Short
3 493
Short Percent
0.02 %
BeatStart